The Latest Breaking News from PFE

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

The healthcare sector is set for significant growth due to advancements in pharma technology, increasing demand for personalized medicines, and resilience even in economic downturns. Therefore, investors might consider buying quality pharmaceutical stocks like Pfizer (PFE), Johnson & Johnson (JNJ), and AbbVie (ABBV) for defensive investing. Read on.

Volatility is back on Wall Street, which is bound to scare some investors. Meanwhile, Pfizer and Starbucks are two high dividend names with limited downside which conservative investors can consider now.

Pfizer has underperformed relative to the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s outlook.

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.

As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.